GnuBio Claims Proof of Principle for Sequencing; Plans to Ship Early Commercial Systems by Year-End

The Harvard University spinout also disclosed that it raised $8 million in private financing last year. It is working on a fast and scalable microfluidics-based sequencing platform priced at less than $50,000 that will allow users to analyze target genes in a single or a thousand samples at the same cost per sample.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.